P-021 A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/Refractory Multiple Myeloma

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01924-4

Jan Frenking, Christine Riedhammer, Britta Besemer, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Deniz Gezer, Sarah Goldman-Mazur, Mathias Hänel, Christine Hanoun, Marion Högner, Katja Kolditz, Igor Kos, Miriam Kull, Theo Leitner, Maximilan Merz, Ivana von Metzler, Christian S. Michel, Raphael Teipel, Marc-Steffen Raab

引用次数: 0

查看原文本刊更多论文

P-021 Talquetamab 在 102 例复发性/难治性多发性骨髓瘤患者中的德国多中心实际应用分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.